Skip to main content
. 2020 May 20;11(7):1934–1943. doi: 10.1111/1759-7714.13485

Figure 1.

Figure 1

Gefitinib resistance in HCC827 GR cells is not due to EGFR T790M mutation. (a) and (b) HCC827, PC‐9, HCC827 GR and PC‐9 GR cells were treated with gefitinib at different concentrations, and CCK‐8 assays were used to assess cell viability (a: Inline graphic HCC827 and Inline graphic HCC827 GR; b: Inline graphic PC‐9 and Inline graphic PC‐9 GR). (c) Next‐generation DNA sequencing was used to analyze EGFR for the DNA substitution corresponding to the T790M mutation.